These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25642319)

  • 1. New antiepileptic medication linked to blue discoloration of the skin and eyes.
    Clark S; Antell A; Kaufman K
    Ther Adv Drug Saf; 2015 Feb; 6(1):15-9. PubMed ID: 25642319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
    Garin Shkolnik T; Feuerman H; Didkovsky E; Kaplan I; Bergman R; Pavlovsky L; Hodak E
    JAMA Dermatol; 2014 Sep; 150(9):984-9. PubMed ID: 25006968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures.
    Amabile CM; Vasudevan A
    Pharmacotherapy; 2013 Feb; 33(2):187-94. PubMed ID: 23386597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.
    Faulkner MA; Burke RA
    Expert Opin Drug Saf; 2013 Nov; 12(6):847-55. PubMed ID: 23883095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezogabine skin discoloration is reversible after discontinuation.
    Mathias SV; Abou-Khalil BW
    Epilepsy Behav Case Rep; 2017; 7():61-63. PubMed ID: 28417066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
    Splinter MY
    Clin Ther; 2012 Sep; 34(9):1845-56.e1. PubMed ID: 22917854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures.
    Weisenberg JL; Wong M
    Neuropsychiatr Dis Treat; 2011; 7():409-14. PubMed ID: 21792307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults.
    Splinter MY
    J Cent Nerv Syst Dis; 2013 Oct; 5():31-41. PubMed ID: 24250245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezogabine: an evaluation of its efficacy and safety as adjunctive therapy for partial-onset seizures in adults.
    Yamada M; Welty TE
    Ann Pharmacother; 2012 Oct; 46(10):1358-67. PubMed ID: 22991134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy.
    Ciliberto MA; Weisenberg JL; Wong M
    Drug Healthc Patient Saf; 2012; 4():81-6. PubMed ID: 22888276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials.
    Slater J; Chung S; Huynh L; Duh MS; Gorin B; McMicken C; Ziemann A; Isojarvi J
    Epilepsy Res; 2018 Jul; 143():120-129. PubMed ID: 29784458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Investigation into Retigabine (Ezogabine) Associated Dyspigmentation in Rat Eyes by MALDI Imaging Mass Spectrometry.
    Groseclose MR; Castellino S
    Chem Res Toxicol; 2019 Feb; 32(2):294-303. PubMed ID: 30638013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezogabine treatment of childhood absence epilepsy.
    Vossler DG; Yilmaz U
    Epileptic Disord; 2014 Mar; 16(1):121-4. PubMed ID: 24659629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabine.
    Brickel N; Derossett S; Buraglio M; Evans C; Jones S
    Ther Clin Risk Manag; 2013; 9():207-13. PubMed ID: 23671389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study.
    Lim KS; Lotay N; White R; Kwan P
    Epilepsy Behav; 2016 Aug; 61():224-230. PubMed ID: 27376872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ezogabine: a novel antiepileptic as adjunctive therapy for partial onset seizures.
    Owen RT
    Drugs Today (Barc); 2010 Nov; 46(11):815-22. PubMed ID: 21225020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezogabine: development and role in the management of epileptic seizures.
    Verma A; Kumar R; Kumar M
    Mini Rev Med Chem; 2013 Apr; 13(5):697-705. PubMed ID: 22931529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed long-term maintenance treatment leading to multiple finger amputation; cardiovascular complications after energy drink consumption; compartment syndrome due to extravasation of intravenous contrast; blue-gray mucocutaneous discoloration with ezogabine.
    Mancano MA
    Hosp Pharm; 2015 Feb; 50(2):99-112. PubMed ID: 25717203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.
    Rudzinski LA; Vélez-Ruiz NJ; Gedzelman ER; Mauricio EA; Shih JJ; Karakis I
    J Investig Med; 2016 Aug; 64(6):1087-101. PubMed ID: 27252470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.